The present disclosure provides is a short in vivo half-life and in vivo unstable recombinant microplasmin, wherein the recombinant microplasmin can be a mutant type and wild type and is expressed in a bacteria host, can be purified, or can be refolded and purified in case expressed as an insoluble inclusion body, producing an active thrombolytic agent. The present disclosure also provides the pharmaceutical composition comprising the recombinant microplasmin and method of treating thromboembolism related diseases including the administration of the pharmaceutical composition.

The present invention relates to a method for preventing and/or treating a drug-induced renal tissue injury and its related conditions in a subject, comprising administering an effective amount of plasminogen to the subject. The present invention further relates to a medicament, a pharmaceutical composition, an article of manufacture, and a kit comprising plasminogen which are useful for preventing and/or treating a drug-induced renal tissue injury and its related conditions in a subject.

The present invention relates to a method for preventing and/or treating a fat metabolism disorder and its related conditions, comprising administering an effective amount of plasminogen to a subject susceptible to or suffering from a fat metabolism disorder and its related conditions, to reduce an abnormal fat deposition at various sites of the body, thereby achieving the purpose of preventing and/or treating a fat metabolism disorder and its related conditions or complications.

The present invention relates to a method for preventing and/or treating overweight/obesity and their related conditions, comprising administering an effective amount of plasminogen to a subject susceptible to or suffering from obesity and its related conditions, to reduce an abnormal/excessive fat deposition at various sites of the body. The present invention further relates to a medicament for preventing and/or treating obesity, and its use in the preparation of a medicament.

The present invention relates to a method for preventing and treating skin fibrosis, comprising administering an effective amount of plasminogen to a subject.

The present invention relates to a method for preventing and treating hepatic fibrosis, comprising administering an effective amount of plasminogen to a subject.

The present invention relates to a method for preventing and treating pulmonary fibrosis, comprising administering an effective amount of plasminogen to a subject.

The present invention relates to a method for restoring a balance between glucagon and insulin to normal, comprising administering an effective amount of plasminogen to a subject; furthermore, the present invention relates to a medicament for restoring a balance between glucagon and insulin to normal.

The present invention relates to a novel method for treating diabetes mellitus, comprising administering an effective amount of plasminogen to a diabetic subject; furthermore, the present invention relates to a medicament for treating diabetes mellitus.

The present invention relates to a method for promoting insulin secretion comprising administering an effective amount of plasminogen to a subject; furthermore, the present invention relates to a medicament for promoting insulin secretion.